DUBLIN--(BUSINESS WIRE)--The "2018 Primary Sclerosing Cholangitis Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
Primary sclerosing cholangitis (PSC) is a chronic progressive GI disorder that affects the bile volume in the gall bladder. The slowly progressing condition causes inflammation and scaring of bile ducts, which results in improper flow of the digestive liquid.
Around 30 companies and universities are focusing on developing treatment options for Primary sclerosing cholangitis.
To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Primary sclerosing cholangitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Primary sclerosing cholangitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Primary sclerosing cholangitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Key Topics Covered:
1 Tables & Figures
2 Primary Sclerosing Cholangitis Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Primary Sclerosing Cholangitis Pipeline Snapshot
2.3 Primary Sclerosing Cholangitis Pipeline by Phase
2.4 Primary Sclerosing Cholangitis Pipeline by Company
2.5 Primary Sclerosing Cholangitis Pipeline by Mechanism of Action
3 Primary Sclerosing Cholangitis- Company Wise Pipeline Analysis
- Acorda Therapeutics Inc
- Albireo Pharma Inc
- ChemomAb Ltd
- Conatus Pharmaceuticals Inc
- Dr. Falk Pharma GmbH
- DURECT Corp
- Gilead Sciences
- HighTide Biopharmaceutical
- Immune Pharmaceuticals Inc
- Intercept Pharmaceuticals Inc
- NGM Biopharmaceuticals Inc
- Noxopharm Ltd
- Orbsen Therapeutics Ltd
- PharmAkea Therapeutics
- Sancilio & Company Inc
- Shire Plc
- Tobira Therapeutics
4 Primary Sclerosing Cholangitis R&D Pipeline Snapshots
- Drug wise Pipeline Details
- Therapeutic Candidate Name
- Co-Developer/ License Partner
- Orphan Drug Designation
- Development Phase
- Mechanism of Action
- Current Status
- Ongoing Clinical Trial Details
5 Recent Developments in Primary Sclerosing Cholangitis Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/8lc5tj/2018_primary?w=4